KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Boston Scientific (BSX) EBT (2016 - 2026)

Boston Scientific's EBT history spans 18 years, with the latest figure at $1.2 billion for Q1 2026.

  • On a quarterly basis, EBT rose 44.35% to $1.2 billion in Q1 2026 year-over-year; TTM through Mar 2026 was $3.7 billion, a 50.95% increase, with the full-year FY2025 number at $3.4 billion, up 48.33% from a year prior.
  • EBT hit $1.2 billion in Q1 2026 for Boston Scientific, up from $700.0 million in the prior quarter.
  • Over the last five years, EBT for BSX hit a ceiling of $1.2 billion in Q1 2026 and a floor of $156.0 million in Q1 2022.
  • Historically, EBT has averaged $585.6 million across 5 years, with a median of $585.0 million in 2024.
  • The widest YoY moves for EBT: up 232.77% in 2022, down 52.0% in 2022.
  • Tracing BSX's EBT over 5 years: stood at $396.0 million in 2022, then rose by 27.53% to $505.0 million in 2023, then increased by 15.84% to $585.0 million in 2024, then rose by 19.66% to $700.0 million in 2025, then surged by 66.0% to $1.2 billion in 2026.
  • Business Quant data shows EBT for BSX at $1.2 billion in Q1 2026, $700.0 million in Q4 2025, and $939.0 million in Q3 2025.